Company Research
DaVita Inc. (DVA)
First analyzed: 2026-09-29
Part 1
Company Overview
DaVita is a scaled, largely recurring kidney-care provider whose economics are anchored by U.S. dialysis, while international expansion and value-based integrated kidney care provide growth but add reimbursement, execution and regulatory complexity.
Business Model
Overview
- DaVita provides dialysis and related laboratory services for patients with end-stage kidney disease, primarily through outpatient dialysis centers. It also operates integrated kidney care, international dialysis, clinical research, transplant software and other ancillary businesses.
- The company serves patients directly but is primarily paid by government programs, commercial health insurers, hospitals and other healthcare organizations. Nephrologists and hospitals are important referral and operating partners, while health plans and government programs are the principal economic customers.
Segments And Revenue
- Fiscal 2025 consolidated revenue was approximately $13.643 billion.
- U.S. dialysis generated approximately $11.793 billion, or 86% of consolidated revenue. This segment is the core business and includes outpatient dialysis, inpatient dialysis-related services, administrative services and related laboratory services.
- Other ancillary services generated approximately $1.922 billion, or 14% of consolidated revenue. Within ancillary services, reported 2025 revenue was approximately $1.346 billion from international operations, $542 million from U.S. integrated kidney care and $34 million from U.S. other ancillary activities. These figures are management's segment presentation and include the company's reported classifications.
- International operations represented approximately 10% of consolidated revenue in 2025 and operated 585 outpatient dialysis centers in 14 countries as of December 31, 2025. The international network was concentrated in Brazil, Colombia, Malaysia, Poland, Chile and Germany, with additional operations in the United Kingdom, Ecuador, Saudi Arabia, Panama, Portugal, China, Japan and Singapore.
- As of June 30, 2026, DaVita reported approximately 298,500 patients and 3,266 outpatient dialysis centers, including 2,671 U.S. centers and 595 centers in 14 other countries.
Payor Mix
- For U.S. dialysis patient-service revenue in 2025, approximately 57% came from Medicare and Medicare Advantage, 7% from Medicaid and managed Medicaid, 3% from other government programs and 32% from commercial payors, including hospital dialysis services.
- Government programs covered approximately 89% of U.S. dialysis patients but generated approximately 68% of U.S. dialysis patient-service revenue. Commercial patients were approximately 11% of U.S. dialysis patients but generated approximately 26% of U.S. dialysis patient-service revenue from non-hospital commercial payors.
- Commercial reimbursement rates are generally materially higher than government rates and generate nearly all of DaVita's profits from non-hospital dialysis. This creates a significant earnings sensitivity to commercial-insurance enrollment, contract rates and the transition of patients from commercial coverage to Medicare after the applicable eligibility period.
Recurring And Cyclicality
- Revenue is recurring in the operating sense: dialysis is medically necessary, treatments are delivered multiple times per week and revenue is recognized as services are provided. Patient volume is therefore more durable than demand for elective or discretionary healthcare.
- The business is not subscription-based and revenue is not contractually fixed. It is exposed to treatment volumes, mortality, transplantation, payer mix, reimbursement policy, labor costs, supply costs, collections and regulatory changes.
- DaVita is relatively defensive against ordinary economic cycles, but earnings can be cyclical or volatile through reimbursement changes, commercial-insurance mix, labor inflation, government policy, cybersecurity events and acquisitions. The 2025 filing specifically identified commercial-payer mix as a major profit driver.
History
Origins And Turnaround
- The company was incorporated in 1994 under an earlier corporate name and became Total Renal Care Holdings. In the late 1990s, it was near bankruptcy when Kent Thiry became chairman and chief executive officer.
- In 2000, the company adopted the DaVita name and launched the values-based 'Village' operating culture. The turnaround under Thiry was a foundational milestone that stabilized the company and established its distinctive employee and patient-oriented culture.
Major Acquisitions And Pivots
- In 2005, DaVita acquired Gambro Healthcare, approximately doubling its dialysis-center footprint and materially strengthening its U.S. scale.
- In 2011, the company began international expansion, later building a presence across 14 countries.
- In 2012, DaVita acquired HealthCare Partners for an announced purchase price of approximately $4.42 billion. The transaction expanded DaVita into physician networks and coordinated medical care, and the company was renamed DaVita HealthCare Partners.
- In June 2019, DaVita sold its former DaVita Medical Group business to Optum, a UnitedHealth Group subsidiary, for an aggregate purchase price of approximately $4.34 billion before specified adjustments. The sale refocused the company on kidney care and related businesses.
- The post-2019 strategy has emphasized comprehensive kidney care, integrated kidney care arrangements, international dialysis expansion, home and hospital care, clinical research, transplant-related software and value-based partnerships rather than broad ownership of primary-care medical groups.
Leadership
- Kent Thiry led the company's turnaround beginning in the late 1990s and remained a central figure for nearly two decades.
- Javier Rodriguez, who joined DaVita in 1998 and held operating and payor-contracting roles, became chief executive officer in 2019. He remained CEO as of the 2025 Form 10-K and the company's 2026 investor materials.
- David Maughan became chief operating officer of DaVita Kidney Care in September 2024 after holding several senior roles at the company.
- Robert Lang has served as president and CEO of DaVita International since April 2017 and has overseen the international business's expansion to 14 countries.
Milestones Shaping The Current Company
- The 1990s turnaround created the operating culture and management system that underpin DaVita's scale.
- The Gambro acquisition established a much larger dialysis platform.
- The HealthCare Partners acquisition demonstrated an attempt to broaden into integrated healthcare delivery.
- The 2019 medical-group sale reversed that diversification and left DaVita primarily focused on kidney care, dialysis and adjacent services.
- The current model combines a mature U.S. dialysis base with higher-growth but smaller businesses in international dialysis and risk-based integrated kidney care.
Strengths and Moat
Competitive Advantages
- Scale and density: DaVita operated or provided administrative services to 2,657 U.S. outpatient dialysis centers serving approximately 200,500 patients at December 31, 2025. A large network can spread clinical, technology, compliance, purchasing, laboratory and administrative costs across many centers.
- Clinical and operating know-how: Dialysis is a complex, highly regulated service requiring clinical protocols, trained staff, nephrologist relationships, quality reporting and reliable supply and scheduling systems. DaVita reports a long record of strong performance under CMS dialysis quality programs.
- Referral and payor relationships: Relationships with nephrologists, hospitals and commercial payors support patient referrals, medical-director coverage, hospital contracts and reimbursement negotiations. These relationships are difficult for a small entrant to replicate quickly.
- Patient and treatment data: A large longitudinal patient base can support quality measurement, care coordination, integrated kidney care and operational benchmarking. This advantage is more valuable if DaVita can convert data and clinical scale into lower total cost for payors.
- Integrated-care platform: DaVita IKC had approximately 66,000 patients in risk-based integrated care arrangements and an additional 9,400 patients in other integrated care arrangements as of December 31, 2025. These arrangements provide a path beyond fee-for-service dialysis, although they also expose DaVita to medical-cost and execution risk.
- Regulatory and compliance infrastructure: Operating thousands of centers across many jurisdictions requires substantial compliance, billing, quality and risk-management capabilities. This creates a meaningful barrier to entry for smaller providers.
Main Competitors
- Fresenius Medical Care is the largest and most direct global competitor. It also manufactures dialysis equipment and supplies, which can provide vertical-integration and purchasing advantages that DaVita generally does not possess.
- DaVita also competes with large and medium-sized dialysis providers, independent nephrologists, physician-owned centers, private-equity-backed kidney-care companies, hospitals and emerging technology or pre-dialysis providers.
- In integrated kidney care, competition includes health plans, physician groups, value-based kidney-care companies and other organizations seeking to manage chronic kidney disease and reduce avoidable medical spending.
Where Davita Wins
- DaVita is strongest where network scale, operating consistency, clinical infrastructure and relationships with nephrologists and payors matter.
- Its large U.S. footprint supports patient access, centralized capabilities and negotiating experience, while its kidney-focused specialization may allow faster operational learning than a diversified general healthcare company.
- Its international platform and integrated-care capabilities give it additional growth options beyond mature U.S. dialysis.
Where Davita Loses Or Is Vulnerable
- Fresenius has a broader vertically integrated position through dialysis equipment and supplies, potentially creating cost and supply-chain advantages.
- DaVita's profits are disproportionately dependent on a relatively small commercial-patient population because commercial reimbursement is much higher than government reimbursement.
- The company has limited control over Medicare, Medicaid and other government reimbursement rules, which account for most U.S. dialysis revenue and patients.
- Labor availability, wage inflation, clinician recruitment and retention can pressure margins because dialysis is labor-intensive and requires specialized staff.
- Large scale does not eliminate competition for medical directors, acquisition targets, patients, hospital relationships and commercial contracts. Smaller or newer entrants may also face fewer legacy compliance or infrastructure burdens.
- International growth adds currency, reimbursement, political, regulatory and integration risks and has historically produced lower margins than U.S. dialysis.
Moat Durability
- Interpretation: DaVita has a real but not impregnable moat. The strongest elements are local network density, clinical operating experience, physician and payor relationships, regulatory infrastructure and accumulated patient data.
- The moat is durable because dialysis is recurring, regulated and operationally difficult, while the patient population requires ongoing care. However, the moat is not a classic pricing-power moat: reimbursement is heavily shaped by government policy, and commercial payors can exert significant negotiating pressure.
- Long-term durability depends on maintaining quality and physician relationships, preserving commercial reimbursement, controlling labor costs, converting scale into lower total kidney-care costs and adapting to home dialysis, transplantation, new drugs and technologies that could reduce or change dialysis demand.
- Overall assessment: strong incumbent advantages in U.S. dialysis, moderate advantages in integrated kidney care, and a more variable moat internationally.
Bottom line
- DaVita is primarily a U.S. dialysis company, supplemented by international dialysis, integrated kidney care and other kidney-related services.
- Its differentiation comes from scale, clinical and operating infrastructure, physician and payor relationships and a specialized kidney-care platform, not from proprietary equipment or unconstrained pricing power.
- The most important long-term issues are commercial-payer mix, government reimbursement, labor economics, the ability to grow profitable value-based care and whether new therapies or care modalities reduce the need for conventional dialysis.
Sources
No verified source links were returned.
Part 2
Updated 2026-11-18Current Situation & Why the Stock Is in a Rut
DaVita remains highly cash-generative and Q3 2026 results were above reported estimates, but the stock remains under pressure because organic dialysis growth is barely positive, revenue per treatment is slipping sequentially, costs are rising faster than volume, and Q3 included a $62 million impairment plus weaker ancillary results.
Recent Performance
Period Covered
Q1 2026 through Q3 2026, with context from Q4 2025 and the October 29, 2026 Q3 release
Earnings
Quarter
Q1 2026
Report Date
2026-05-05
Facts
- Revenue was approximately $3.416 billion, up from $3.224 billion in Q1 2025.
- GAAP diluted EPS was $2.87 versus $2.00 in Q1 2025.
- Operating income was $482 million, or a 14.1% margin, versus $439 million and approximately 13.6% in Q1 2025.
- Normalized non-acquired treatment growth was 0.1% year over year.
- Revenue per treatment was $417.59 and patient-care cost per treatment was $280.11.
- Management raised 2026 adjusted operating-income guidance to $2.150 billion-$2.250 billion and adjusted EPS guidance to $14.10-$15.20.
- Reported secondary estimates indicated EPS and revenue exceeded consensus, but the consensus figures were not independently verified.
Interpretation
Q1 was operationally strong, but the near-zero underlying treatment growth limited confidence that earnings growth was being driven by durable organic demand.
Quarter
Q2 2026
Report Date
2026-08-04
Stock Reaction Date
2026-08-05
Facts
- Revenue was $3.554 billion, up approximately 5.2% year over year.
- GAAP diluted EPS was $4.02 versus $2.95 in Q2 2025.
- Operating income was $579 million, or a 16.3% margin.
- Normalized non-acquired treatment growth was 0.3% year over year.
- Revenue per treatment declined sequentially to $415.87 from $417.59.
- Patient-care cost per treatment declined sequentially to $277.40 from $280.11, but first-half patient-care cost per treatment increased to $278.74 from $270.05.
- Management reaffirmed rather than raised 2026 guidance of $2.150 billion-$2.250 billion in adjusted operating income, $14.10-$15.20 in adjusted EPS and $1.0 billion-$1.25 billion in free cash flow.
- The stock reportedly fell sharply after the release despite a reported EPS and revenue beat. The precise percentage is secondary-source data.
Interpretation
The Q2 selloff was primarily an expectations reset. Investors wanted another guidance increase, while revenue per treatment weakened and normalized volume growth remained minimal.
Quarter
Q3 2026
Report Date
2026-10-29
Facts
- Revenue was $3.578 billion versus $3.420 billion in Q3 2025.
- GAAP diluted EPS was $3.40 versus $2.29 in Q3 2025; adjusted diluted EPS was $3.82.
- Operating income was $499 million, or a 14.0% margin; adjusted operating income was $561 million, or a 15.7% margin.
- Operating cash flow was $519 million and free cash flow was $276 million.
- Normalized non-acquired treatment growth improved only modestly to 0.4% year over year. Average treatments per normalized day increased 0.5% year over year.
- Revenue per treatment declined sequentially to $415.25 from $415.87.
- Patient-care cost per treatment increased sequentially to $280.22 from $277.40 and was $279.24 for the first nine months, up $8.01, or 3.0%, from the prior-year period.
- DaVita recorded a $62 million goodwill and other asset impairment charge related to China, reducing attributable net income by approximately $27 million after the noncontrolling-interest effect.
- Integrated kidney care operating income fell to $4 million from $40 million in Q2, while international operations reported a $16 million operating loss versus $25 million of operating income in Q2.
- Management raised the low end of 2026 adjusted operating-income guidance to $2.175 billion from $2.150 billion and the low end of adjusted EPS guidance to $14.30 from $14.10. The high ends remained $2.250 billion and $15.20, and free-cash-flow guidance remained $1.0 billion-$1.25 billion.
- Reported secondary estimates indicated adjusted EPS of approximately $3.82 versus approximately $3.57 expected and revenue of approximately $3.58 billion versus approximately $3.52 billion expected. The expectation figures were not independently verified.
- Secondary market commentary reported an approximately 7.4% after-hours decline following the release. The exact closing reaction was not independently verified.
Interpretation
Q3 was a headline beat with a modest guidance improvement, but the quality of the beat was mixed. The core dialysis business still showed almost no organic volume growth, revenue per treatment declined, patient-care cost per treatment rose, and ancillary earnings were volatile.
Quarter
Q4 2025
Report Date
2026-02-02
Facts
- Revenue was $3.620 billion.
- Adjusted diluted EPS was $3.40.
- Operating income was $561 million, or a 15.5% margin.
- Normalized non-acquired treatment growth was negative 0.6% year over year.
- Management initiated 2026 adjusted EPS guidance of $13.60-$15.00 and free-cash-flow guidance of $1.0 billion-$1.25 billion.
Interpretation
Q4 established the pattern that continued into 2026: strong earnings and cash flow, but little underlying dialysis-volume growth.
Specific Events That Put Pressure On The Stock
Date
2025-10-29
Event
Q3 2025 operating weakness and cybersecurity costs
Facts
- Average daily U.S. dialysis treatments declined 0.5% sequentially.
- The company incurred approximately $12 million of cybersecurity incident-related charges in Q3 2025, with approximately $25 million of related charges for the first nine months of 2025.
Importance
This increased investor sensitivity to volume, labor, patient-care costs, operational execution and cybersecurity risk.
Date
2026-08-05
Event
Post-Q2 2026 selloff
Facts
- The negative market reaction occurred despite reported revenue and EPS beats.
- The apparent drivers were the lack of another material guidance raise, low normalized treatment growth and sequentially lower revenue per treatment.
Importance
This appears to have been the principal event establishing the current de-rating.
Date
2026-10-29
Event
Q3 2026 results and mixed earnings quality
Facts
- Q3 exceeded reported secondary consensus, but GAAP operating margin fell to 14.0% from 16.3% in Q2.
- The quarter included a $62 million China impairment, a sequential decline in revenue per treatment and a sequential increase in patient-care cost per treatment.
- Integrated kidney care profit fell sharply sequentially and international operations swung to an operating loss.
Importance
The market had additional evidence that DaVita's earnings are strong but uneven and still dependent on reimbursement, cost control and capital allocation rather than robust organic volume.
Date
2026-08-25
Event
Humana value-based-care partnership
Facts
- DaVita announced a partnership with Humana covering more than 10,000 chronic-kidney-disease patients.
- The program launched July 1, 2026 and is intended to delay or prevent dialysis and reduce hospitalizations.
Importance
Strategically positive, but its near-term financial contribution and scalability remain unproven.
The Bear Case
Company Specific Problems
Issue
Organic dialysis growth remains close to zero
Evidence
Normalized non-acquired treatment growth was negative 0.6% in Q4 2025, 0.1% in Q1 2026, 0.3% in Q2 and 0.4% in Q3.
Why It Matters
With little volume growth, EPS increasingly depends on reimbursement increases, payer mix, operating efficiency, acquisitions and share repurchases.
Issue
Revenue per treatment is weakening sequentially
Evidence
Revenue per treatment declined from $417.59 in Q1 to $415.87 in Q2 and $415.25 in Q3.
Why It Matters
DaVita is exposed to commercial-payer mix, government reimbursement and changes in patient insurance coverage. Sequential deterioration makes the earnings model more sensitive to payer economics.
Issue
Cost inflation is exceeding volume growth
Evidence
Nine-month patient-care cost per treatment rose 3.0% year over year to $279.24. The company cited compensation, wage rates, medical supplies, insurance and health-benefit costs.
Why It Matters
If reimbursement growth slows while labor and medical costs remain elevated, operating-margin gains can reverse.
Issue
Ancillary earnings are volatile
Evidence
Integrated kidney care operating income declined from $40 million in Q2 to $4 million in Q3. International operations moved from $25 million of operating income in Q2 to a $16 million operating loss in Q3.
Why It Matters
The non-dialysis businesses have not yet demonstrated consistent, recurring earnings sufficient to offset stagnant core volume.
Issue
Leverage limits flexibility
Evidence
Debt principal outstanding was $10.832 billion at September 30, 2026 versus $10.345 billion at December 31, 2025. The company also completed a $500 million Term Loan B-2 transaction in 2026.
Why It Matters
High debt makes the equity more sensitive to interest rates, refinancing costs and any decline in operating cash flow. Continued buybacks can support EPS but may slow deleveraging.
Issue
Impairment and execution risk
Evidence
DaVita recorded a $62 million goodwill and other asset impairment related to China in Q3 2026.
Why It Matters
The charge may be non-cash, but it signals that some international or ancillary assets are underperforming expectations.
Issue
Cybersecurity and operational risk
Evidence
The 2025 cybersecurity incident caused remediation costs and temporary operational disruption.
Why It Matters
A repeat incident or billing and network disruption could pressure cash flow and damage payer, patient and investor confidence.
Macro And Sector Headwinds
- Medicare, Medicaid and Medicare Advantage reimbursement changes.
- Commercial-payer enrollment, reimbursement negotiations and payer-mix changes.
- Potential changes to charitable premium assistance or policies that affect commercial coverage.
- Labor shortages, wage inflation, health-benefit inflation and medical-supply costs.
- Competition from Fresenius Medical Care, independent providers, home dialysis, new drugs, devices and alternative kidney-care models.
- Higher interest rates or wider credit spreads because DaVita uses substantial debt financing.
- A mature dialysis market with defensive demand but limited organic treatment growth.
Valuation
Current Snapshot
- The November 10, 2026 market-data snapshot showed a share price of approximately $185.54 and a trailing P/E ratio of approximately 13.7.
- Using the midpoint of the latest 2026 adjusted EPS guidance of $14.75, the stock trades at approximately 12.6 times midpoint adjusted EPS.
- Using the midpoint of adjusted operating-income guidance, the valuation is consistent with a low-teens earnings multiple rather than a distressed multiple.
- The supplied negative price-to-book ratio is not economically useful because treasury-stock activity and the capital structure can produce negative book equity.
- DaVita appears reasonably valued versus its recent history, but not obviously cheap enough to ignore stagnant volume, payer risk and leverage.
- Peer comparison with Fresenius Medical Care is imperfect because fiscal periods, estimates and capital structures differ. An exact current peer premium or discount was not independently verified.
Assessment
The valuation provides some downside support because the stock trades near 12.6 times midpoint 2026 adjusted EPS, but the multiple is not so low that the market is pricing in no growth. It is better described as moderately valued with a risk discount than as a deep-value situation.
Analyst And Short Interest
Item
Analyst activity
Details
- Secondary market-data reports indicated that Barclays cut its price target from $224 to $216 on November 2, 2026.
- Prior secondary reports indicated that Weiss Ratings downgraded DaVita from Buy to Hold on September 24, 2026.
- TD Cowen was reported as upgrading DaVita from Hold to Buy and raising its price target from $201 to $220 on August 7, 2026.
- Truist was reported as reducing its price target from $250 to $215 while retaining a Hold rating.
- These actions were not independently verified through the underlying broker research notes and should be treated as reported secondary data.
Item
Short interest
Details
- As of the October 15, 2026 settlement date, reported short interest was approximately 4.91 million shares.
- MarketBeat reported short interest equal to approximately 7.84% of public float.
- Float percentages vary by vendor and denominator, so the percentage should be treated as approximate.
- Short interest is meaningful enough to amplify post-earnings volatility but is not extreme by itself.
Turnaround or Value Trap?
Bull Case
- DaVita delivers the midpoint or better of 2026 adjusted EPS guidance of $14.30-$15.20 and converts guidance into $1.0 billion-$1.25 billion of free cash flow.
- Normalized non-acquired treatment growth rises above 1% year over year and remains positive for multiple quarters.
- Revenue per treatment stabilizes sequentially and resumes year-over-year growth.
- Patient-care cost per treatment grows more slowly than revenue per treatment, allowing operating margins to remain near or above 16% on a normalized basis.
- Integrated kidney care produces recurring positive operating income rather than volatile quarter-to-quarter shared-savings gains.
- Net debt begins to decline while buybacks become less central to EPS growth.
- The Humana partnership creates measurable pre-dialysis and value-based-care growth.
Bear Case
- Treatment growth remains near zero while EPS growth depends on reimbursement, cost control and share repurchases.
- Revenue per treatment continues to decline because of payer mix, commercial-rate pressure or lower reimbursement.
- Patient-care costs rise faster than revenue, pushing operating margins back toward 2025 levels.
- Management cuts 2026 guidance or gives a weak 2027 outlook.
- Debt remains high while buybacks continue, reducing balance-sheet flexibility.
- Integrated kidney care remains volatile and fails to offset stagnant dialysis volume.
- Regulatory, payer or litigation developments reduce reimbursement or commercial coverage.
What Would Signal A Turn
- Normalized non-acquired treatment growth above 1% year over year for at least two consecutive quarters.
- Revenue per treatment stabilizing sequentially and growing year over year.
- Patient-care cost per treatment growing below revenue per treatment.
- Normalized operating margin sustained around 16% or higher without relying on one-time items.
- A meaningful guidance raise for adjusted operating income, adjusted EPS or free cash flow.
- Net debt declining for at least two consecutive quarters.
- Integrated kidney care producing recurring positive operating income.
- Evidence that commercial-payer negotiations and payer mix are stabilizing.
Key Catalysts And Dates
Date
2026-10-29
Event
Q3 2026 earnings release
Status
Completed.
Watch
- Management's explanation for the sequential revenue-per-treatment decline
- Whether Q3 cost pressure is temporary or persistent
- The volatility in integrated kidney care and international results
- The effect of the China impairment on future capital allocation
Date
2026-11-10
Event
Current post-Q3 assessment
Status
The latest verified quarterly information available in the reviewed sources.
Watch
- Whether the stock stabilizes after the Q3 reaction
- Analyst estimate revisions for 2027
- Short-interest changes following the earnings release
Date
Future 2026 and 2027 reimbursement updates
Event
Medicare, Medicare Advantage, Medicaid and commercial-payer decisions
Status
Specific future dates were not verified.
Watch
- Actual 2027 reimbursement implementation
- Commercial-payer rates and payer mix
- Policies affecting premium assistance and government coverage
Date
2027 earnings reports
Event
Proof of normalized growth or structural stagnation
Status
Exact company-confirmed dates were not verified.
Watch
- Treatment growth above 1%
- Revenue per treatment
- Patient-care cost per treatment
- Free-cash-flow conversion
- Net debt reduction
Assessment
DaVita currently looks more like a temporarily de-rated mature cash generator than a clear value trap, but the evidence is not decisive. The recovery case improved modestly because Q3 exceeded reported estimates and management raised the low end of guidance, yet the core operating pattern remains weak: volume growth is below 1%, revenue per treatment is declining sequentially, costs are rising, and ancillary earnings are volatile. The stock needs proof of improving organic treatment growth and stable unit economics before the low-teens multiple can be viewed as clearly undervalued.
Evidence Assessment
Conclusion
The evidence is mixed but currently more consistent with a temporary valuation and expectations reset than with a proven structural breakdown.
Supporting Temporary View
- Q1, Q2 and Q3 2026 all produced reported earnings and revenue beats versus secondary consensus estimates.
- Management maintained or increased 2026 guidance rather than cutting it.
- Nine-month operating cash flow was $1.330 billion and free cash flow was $672 million.
- The core U.S. dialysis segment generated $1.588 billion of operating income during the first nine months.
- Q3 normalized non-acquired treatment growth improved from 0.3% to 0.4%, although the improvement was small.
- A proposed 2027 ESRD reimbursement rule was described in the filing as implying a 2.7% average reimbursement increase for freestanding facilities, subject to implementation and other adjustments.
Supporting Structural Risk View
- Normalized non-acquired treatment growth remained below 0.5% for four consecutive reported quarters.
- Revenue per treatment declined sequentially in both Q2 and Q3.
- Nine-month patient-care cost per treatment increased 3.0% year over year.
- The company remains heavily exposed to reimbursement, payer mix, labor costs and government policy.
- Debt principal increased to $10.832 billion at September 30, 2026.
- Integrated kidney care and international results were volatile in Q3.
- The China impairment indicates that at least part of the broader platform has not met prior expectations.
What Would Change The Assessment
Two consecutive quarters of treatment growth above 1%, stable or rising revenue per treatment, patient-care costs growing below revenue per treatment and net-debt reduction would strengthen the temporary-problem thesis. A guidance cut, additional impairments, recurring sequential declines in revenue per treatment, renewed margin compression or materially weaker free cash flow would make the structural-problem thesis more persuasive.
Bottom line
DaVita is a dialysis and kidney-care services company whose earnings are supported by recurring treatment demand, reimbursement, operating discipline and substantial free cash flow. The stock is stuck because investors are questioning whether sub-1% organic treatment growth, weakening revenue per treatment, rising unit costs, leverage and volatile ancillary results justify even a low-teens earnings multiple. The next decisive indicators are treatment growth, revenue per treatment, patient-care cost per treatment, integrated-kidney-care profitability, guidance and net-debt reduction in the next two quarters.
Sources
- DaVita Q3 2026 earnings release
- DaVita Q3 2026 Form 10-Q
- DaVita Q2 2026 Form 10-Q
- DaVita Q2 2026 earnings release
- DaVita Q1 2026 earnings release
- DaVita Q4 2025 earnings release
- DaVita Q3 2025 Form 8-K earnings exhibit
- DaVita Humana value-based-care partnership
- DaVita Q3 2026 earnings estimates and transcript summary
- DaVita earnings estimates and reported consensus comparison
- DaVita analyst ratings and price-target changes
- DaVita analyst ratings and price targets
- DaVita analyst ratings history
- DaVita Wall Street Zen rating change
- DaVita analyst price-target update
- DaVita market price and valuation snapshot
- DaVita Q3 2026 market-reaction commentary
Research history
The current situation refreshes after a gap or at the 30-day consecutive Top-10 refresh point. Previous analyses are retained.